価格表

在庫・価格 : 2025年04月26日 03時32分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
NT-proBNP ELISA Kit (12×8tests)
データシート
SK-1204 BMCバイオメディカ
BIOMEDICA Medizinprodukte GmbH
1 kit ¥144,000
(未発注)
追加

在庫・価格 : 2025年04月26日 03時32分 現在

NT-proBNP ELISA Kit (12×8tests)

  • 商品コード:SK-1204
  • メーカー:BMC
  • 包装:1kit
  • 価格: ¥144,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Ueland T et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005 May;111(19):2461-8
Ueland T et al
2005/01/01
PubMed
2 L坦pez B et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc. Res. 2013 Jul;99(1):111-20
L坦pez B et al
2013/01/01
PubMed
3 Marney AM et al. Changes in B-type natriuretic peptide and BMI following Roux-en-Y gastric bypass surgery. Diabetes Care 2014 Apr;37(4):e70-1
Marney AM et al
2014/01/01
PubMed
4 Staudt A et al. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Ther Apher Dial 2006 Feb;10(1):42-8
Staudt A et al
2006/01/01
PubMed
5 Stanciu AE et al. Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer. Scand. J. Clin. Lab. Invest. 2016 Dec;76(8):626-631
Stanciu AE et al
2016/01/01
PubMed
6 Rosolova H et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic--a report from the EuroHeart Failure Survey. Eur. J. Heart Fail. 2005 Aug;7(5):780-3
Rosolova H et al
2005/01/01
PubMed
7 Riad A et al. Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy. J. Biol. Chem. 2012 Aug;287(32):27236-43
Riad A et al
2012/01/01
PubMed
8 Niccoli G et al. NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. Cardiovasc Revasc Med ;17(3):162-8
Niccoli G et al
PubMed
9 Jarai R et al. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur. Heart J. 2005 Feb;26(3):250-6
Jarai R et al
2005/01/01
PubMed
10 H端lsmann M et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur. Heart J. 2002 Jun;23(11):886-91
H端lsmann M et al
2002/01/01
PubMed
11 Hammerer-Lercher A et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 2004 Jul;50(7):1174-83
Hammerer-Lercher A et al
2004/01/01
PubMed
12 Hammerer-Lercher A et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin. Chim. Acta 2001 Aug;310(2):193-7
Hammerer-Lercher A et al
2001/01/01
PubMed
13 Zheng YG et al. Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension. Heart Lung Circ 2015 Jun;24(6):566-72
Zheng YG et al
2015/01/01
PubMed
14 Li X et al. Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovasc Disord 2014 May;14:67
Li X et al
2014/01/01
PubMed
15 Berger R et al. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur. J. Clin. Invest. 2005 Jan;35(1):24-31
Berger R et al
2005/01/01
PubMed
16 Niessner A et al. Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adrenocortical steroids? Eur. J. Endocrinol. 2003 Dec;149(6):555-9
Niessner A et al
2003/01/01
PubMed
17 Mir TS et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003 Oct;112(4):896-9
Mir TS et al
2003/01/01
PubMed
18 Stanek B et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J. Am. Coll. Cardiol. 2001 Aug;38(2):436-42
Stanek B et al
2001/01/01
PubMed
19 Berger R et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002 May;105(20):2392-7
Berger R et al
2002/01/01
PubMed
20 Hoffmann U et al. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin. Lab. 2005;51(7-8):373-9
Hoffmann U et al
2005/01/01
PubMed
21 Molhoek SG et al. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 2004 Jan;90(1):97-8
Molhoek SG et al
2004/01/01
PubMed
22 Sin DD et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest 2007 Jan;131(1):156-63
Sin DD et al
2007/01/01
PubMed
23 Kuznetsova T et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009 Mar;2(2):105-12
Kuznetsova T et al
2009/01/01
PubMed
24 McDonald VM et al. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing 2011 Jan;40(1):42-9
McDonald VM et al
2011/01/01
PubMed
25 Abolahrari-Shirazi S et al. Efficacy of combined endurance-resistance training versus endurance training in patients with heart failure after percutaneous coronary intervention: A randomized controlled trial. J Res Med Sci 2018;23:12
Abolahrari-Shirazi S et al
2018/01/01
PubMed
26 Zhang ZY et al. Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. J Am Soc Hypertens 2018 06;12(6):438-447.e4
Zhang ZY et al
2018/01/01
PubMed
27 Zhang Y et al. Serum chloride as a novel marker for adding prognostic information of mortality in chronic heart failure. Clin. Chim. Acta 2018 Aug;483:112-118
Zhang Y et al
2018/01/01
PubMed
28 Stanciu AE et al. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine 2018 03;103:63-68
Stanciu AE et al
2018/01/01
PubMed
29 Stanciu AE et al. NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure. Cytokine 2018 11;111:13-19
Stanciu AE et al
2018/01/01
PubMed
30 Clerico A et al. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin. Chem. 2000 Oct;46(10):1529-34
Clerico A et al
2000/01/01
PubMed
31 Mir TS et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002 Dec;110(6):e76
Mir TS et al
2002/01/01
PubMed
32 Mueller T et al. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin. Chem. 2003 Jun;49(6 Pt 1):976-
Mueller T et al
2003/01/01
PubMed
33 Magnusson M et al. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004 Aug;27(8):1929-35
Magnusson M et al
2004/01/01
PubMed
34 Kupari M et al. Is the pregnancy hormone relaxin an important player in human heart failure? Eur. J. Heart Fail. 2005 Mar;7(2):195-8
Kupari M et al
2005/01/01
PubMed
35 Hermann-Arnhof KM et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin. Chem. 2005 Jan;51(1):138-43
Hermann-Arnhof KM et al
2005/01/01
PubMed
36 Flevari P et al. Coronary and peripheral blood flow changes following biventricular pacing and their relation to heart failure improvement. Europace 2006 Jan;8(1):44-50
Flevari P et al
2006/01/01
PubMed
37 Thackray SD et al. N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population. Eur. Heart J. 2006 Feb;27(4):447-53
Thackray SD et al
2006/01/01
PubMed
38 Manuchehri AM et al. The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. Ann. Clin. Biochem. 2006 May;43(Pt 3):184-8
Manuchehri AM et al
2006/01/01
PubMed
39 Jarai R et al. Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. Wien. Klin. Wochenschr. 2007;119(21-22):626-32
Jarai R et al
2007/01/01
PubMed
40 Kjekshus JK et al. Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur. J. Heart Fail. 2009 Aug;11(8):771-8
Kjekshus JK et al
2009/01/01
PubMed
41 Pande S et al. Pulmonary arterial hypertension in rheumatic mitral stenosis: does it affect right ventricular function and outcome after mitral valve replacement? Interact Cardiovasc Thorac Surg 2009 Sep;9(3):421-5
Pande S et al
2009/01/01
PubMed
42 Wu C et al. [Diagnostic value of NT-proBNP in identifying aortic stenosis patients with heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi 2010 Jul;38(7):579-83
Wu C et al
2010/01/01
PubMed
43 Gali竪 N et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
Gali竪 N et al
2017/01/01
PubMed
44 Sung SH et al. Prognostic impact of body mass index in patients undergoing coronary artery bypass surgery. Heart 2011 Apr;97(8):648-54
Sung SH et al
2011/01/01
PubMed
45 Kotyla PJ et al. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J. Rheumatol. 20
Kotyla PJ et al
2012/01/01
PubMed
46 Kosmala W et al. Left ventricular function impairment in patients with normal-weight obesity: contribution of abdominal fat deposition, profibrotic state, reduced insulin sensitivity, and proinflammatory activation. Circ Cardiovasc Imaging 2012 May;5(3):3
Kosmala W et al
2012/01/01
PubMed
47 Helske S et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur. J. Heart Fail. 2007 Apr;9(4):357-63
Helske S et al
2007/01/01
PubMed
48 Hassan S et al. Does Ramadan Fasting Affect Hydration Status and Kidney Function in CKD Patients? Ann. Nutr. Metab. 2018;72(3):241-247
Hassan S et al
2018/01/01
PubMed
49 Jaroszyナгki A et al. Serum heat shock protein 27 levels predict cardiac mortality in hemodialysis patients. BMC Nephrol 2018 12;19(1):359
Jaroszyナгki A et al
2018/01/01
PubMed
50 Tekin YB et al. Alterations of natriuretic peptides amino-terminal pro B-type natriuretic peptide and amino-terminal pro C-type natriuretic peptide during the pregnancy. J Matern Fetal Neonatal Med 2014 Jul;27(11):1103-7
Tekin YB et al
2014/01/01
PubMed
51 Cole WG et al. Urinary-free amino acids in osteogenesis imperfecta. Bone 1986;7(1):13-5
Cole WG et al
1986/01/01
PubMed
52 Alves PKN et al. Leucine Supplementation Improves Diastolic Function in HFpEF by HDAC4 Inhibition. Cells 2023 Nov;12(21)
Alves PKN et al
2023/01/01
PubMed
53 Kerekes G et al. Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis. Rheumatology (Oxford) 2023 Oct;62(SI3):SI304-SI312
Kerekes G et al
2023/01/01
PubMed
54 Wang K et al. Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment. Front Bioeng Biotechnol 2023;11:1227184
Wang K et al
2023/01/01
PubMed
55 Rammos A et al. The Potential Role of Salivary NT-proBNP in Heart Failure. Life (Basel) 2023 Aug;13(9)
Rammos A et al
2023/01/01
PubMed
  • No.: 1
  • 文献情報:
    Ueland T et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005 May;111(19):2461-8
    Ueland T et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    L坦pez B et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc. Res. 2013 Jul;99(1):111-20
    L坦pez B et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Marney AM et al. Changes in B-type natriuretic peptide and BMI following Roux-en-Y gastric bypass surgery. Diabetes Care 2014 Apr;37(4):e70-1
    Marney AM et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Staudt A et al. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Ther Apher Dial 2006 Feb;10(1):42-8
    Staudt A et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Stanciu AE et al. Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer. Scand. J. Clin. Lab. Invest. 2016 Dec;76(8):626-631
    Stanciu AE et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Rosolova H et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic--a report from the EuroHeart Failure Survey. Eur. J. Heart Fail. 2005 Aug;7(5):780-3
    Rosolova H et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Riad A et al. Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy. J. Biol. Chem. 2012 Aug;287(32):27236-43
    Riad A et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Niccoli G et al. NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. Cardiovasc Revasc Med ;17(3):162-8
    Niccoli G et al
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Jarai R et al. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur. Heart J. 2005 Feb;26(3):250-6
    Jarai R et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    H端lsmann M et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur. Heart J. 2002 Jun;23(11):886-91
    H端lsmann M et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Hammerer-Lercher A et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 2004 Jul;50(7):1174-83
    Hammerer-Lercher A et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Hammerer-Lercher A et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin. Chim. Acta 2001 Aug;310(2):193-7
    Hammerer-Lercher A et al
    2001/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Zheng YG et al. Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension. Heart Lung Circ 2015 Jun;24(6):566-72
    Zheng YG et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Li X et al. Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovasc Disord 2014 May;14:67
    Li X et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Berger R et al. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur. J. Clin. Invest. 2005 Jan;35(1):24-31
    Berger R et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Niessner A et al. Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adrenocortical steroids? Eur. J. Endocrinol. 2003 Dec;149(6):555-9
    Niessner A et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Mir TS et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003 Oct;112(4):896-9
    Mir TS et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Stanek B et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J. Am. Coll. Cardiol. 2001 Aug;38(2):436-42
    Stanek B et al
    2001/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Berger R et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002 May;105(20):2392-7
    Berger R et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Hoffmann U et al. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin. Lab. 2005;51(7-8):373-9
    Hoffmann U et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Molhoek SG et al. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 2004 Jan;90(1):97-8
    Molhoek SG et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Sin DD et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest 2007 Jan;131(1):156-63
    Sin DD et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Kuznetsova T et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009 Mar;2(2):105-12
    Kuznetsova T et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    McDonald VM et al. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing 2011 Jan;40(1):42-9
    McDonald VM et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Abolahrari-Shirazi S et al. Efficacy of combined endurance-resistance training versus endurance training in patients with heart failure after percutaneous coronary intervention: A randomized controlled trial. J Res Med Sci 2018;23:12
    Abolahrari-Shirazi S et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Zhang ZY et al. Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. J Am Soc Hypertens 2018 06;12(6):438-447.e4
    Zhang ZY et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Zhang Y et al. Serum chloride as a novel marker for adding prognostic information of mortality in chronic heart failure. Clin. Chim. Acta 2018 Aug;483:112-118
    Zhang Y et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Stanciu AE et al. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine 2018 03;103:63-68
    Stanciu AE et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Stanciu AE et al. NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure. Cytokine 2018 11;111:13-19
    Stanciu AE et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Clerico A et al. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin. Chem. 2000 Oct;46(10):1529-34
    Clerico A et al
    2000/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Mir TS et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002 Dec;110(6):e76
    Mir TS et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Mueller T et al. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin. Chem. 2003 Jun;49(6 Pt 1):976-
    Mueller T et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Magnusson M et al. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004 Aug;27(8):1929-35
    Magnusson M et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 34
  • 文献情報:
    Kupari M et al. Is the pregnancy hormone relaxin an important player in human heart failure? Eur. J. Heart Fail. 2005 Mar;7(2):195-8
    Kupari M et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 35
  • 文献情報:
    Hermann-Arnhof KM et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin. Chem. 2005 Jan;51(1):138-43
    Hermann-Arnhof KM et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 36
  • 文献情報:
    Flevari P et al. Coronary and peripheral blood flow changes following biventricular pacing and their relation to heart failure improvement. Europace 2006 Jan;8(1):44-50
    Flevari P et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 37
  • 文献情報:
    Thackray SD et al. N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population. Eur. Heart J. 2006 Feb;27(4):447-53
    Thackray SD et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 38
  • 文献情報:
    Manuchehri AM et al. The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. Ann. Clin. Biochem. 2006 May;43(Pt 3):184-8
    Manuchehri AM et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 39
  • 文献情報:
    Jarai R et al. Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. Wien. Klin. Wochenschr. 2007;119(21-22):626-32
    Jarai R et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 40
  • 文献情報:
    Kjekshus JK et al. Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur. J. Heart Fail. 2009 Aug;11(8):771-8
    Kjekshus JK et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 41
  • 文献情報:
    Pande S et al. Pulmonary arterial hypertension in rheumatic mitral stenosis: does it affect right ventricular function and outcome after mitral valve replacement? Interact Cardiovasc Thorac Surg 2009 Sep;9(3):421-5
    Pande S et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 42
  • 文献情報:
    Wu C et al. [Diagnostic value of NT-proBNP in identifying aortic stenosis patients with heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi 2010 Jul;38(7):579-83
    Wu C et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 43
  • 文献情報:
    Gali竪 N et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
    Gali竪 N et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 44
  • 文献情報:
    Sung SH et al. Prognostic impact of body mass index in patients undergoing coronary artery bypass surgery. Heart 2011 Apr;97(8):648-54
    Sung SH et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 45
  • 文献情報:
    Kotyla PJ et al. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J. Rheumatol. 20
    Kotyla PJ et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 46
  • 文献情報:
    Kosmala W et al. Left ventricular function impairment in patients with normal-weight obesity: contribution of abdominal fat deposition, profibrotic state, reduced insulin sensitivity, and proinflammatory activation. Circ Cardiovasc Imaging 2012 May;5(3):3
    Kosmala W et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 47
  • 文献情報:
    Helske S et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur. J. Heart Fail. 2007 Apr;9(4):357-63
    Helske S et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 48
  • 文献情報:
    Hassan S et al. Does Ramadan Fasting Affect Hydration Status and Kidney Function in CKD Patients? Ann. Nutr. Metab. 2018;72(3):241-247
    Hassan S et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 49
  • 文献情報:
    Jaroszyナгki A et al. Serum heat shock protein 27 levels predict cardiac mortality in hemodialysis patients. BMC Nephrol 2018 12;19(1):359
    Jaroszyナгki A et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 50
  • 文献情報:
    Tekin YB et al. Alterations of natriuretic peptides amino-terminal pro B-type natriuretic peptide and amino-terminal pro C-type natriuretic peptide during the pregnancy. J Matern Fetal Neonatal Med 2014 Jul;27(11):1103-7
    Tekin YB et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 51
  • 文献情報:
    Cole WG et al. Urinary-free amino acids in osteogenesis imperfecta. Bone 1986;7(1):13-5
    Cole WG et al
    1986/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 52
  • 文献情報:
    Alves PKN et al. Leucine Supplementation Improves Diastolic Function in HFpEF by HDAC4 Inhibition. Cells 2023 Nov;12(21)
    Alves PKN et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 53
  • 文献情報:
    Kerekes G et al. Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis. Rheumatology (Oxford) 2023 Oct;62(SI3):SI304-SI312
    Kerekes G et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 54
  • 文献情報:
    Wang K et al. Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment. Front Bioeng Biotechnol 2023;11:1227184
    Wang K et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 55
  • 文献情報:
    Rammos A et al. The Potential Role of Salivary NT-proBNP in Heart Failure. Life (Basel) 2023 Aug;13(9)
    Rammos A et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed